Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-existing Liver and/or Renal Dysfunction

BACKGROUND: The safety and efficacy of frontline nilotinib and dasatinib in newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) patients with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed adverse event rates, response rates, and survival r...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Lymphoma Myeloma Leuk
Auteurs principaux: Sasaki, Koji, Lahoti, Amit, Jabbour, Elias, Jain, Preetesh, Pierce, Sherry, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Pemmaraju, Naveen, Ferrajoli, Alessandra, O’Brien, Susan, Kantarjian, Hagop, Cortes, Jorge
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769134/
https://ncbi.nlm.nih.gov/pubmed/26796981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.12.003
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires